Oral Cancer: Comparison
Please note this is a comparison between Version 2 by Vicky Zhou and Version 1 by Yasusei Kudo.

Chronic inflammation caused by infections has been suggested to be one of the most important cause of cancers. It has recently been shown that there is correlation between intestinal bacteria and cancer development including metastasis. As over 700 bacterial species exist in an oral cavity, it has been concerning that bacterial infection may cause oral cancer. However, the role of bacteria regarding tumorigenesis of oral cancer remains unclear. Several papers have shown that Fusobacterium species deriving the oral cavities, especially, play a crucial role for the development of colorectal and esophageal cancer. F. nucleatum is a well-known oral bacterium involved in formation of typical dental plaque on human teeth and causing periodontal diseases. The greatest characteristic of F. nucleatum is its ability to adhere to various bacteria and host cells. Interestingly, F. nucleatum is frequently detected in oral cancer tissues. Moreover, detection of F. nucleatum is correlated with the clinical stage of oral cancer. Although the detailed mechanism is still unclear, Fusobacterium species have been suggested to be associated with cell adhesion, tumorigenesis, epithelial-to-mesenchymal transition, inflammasomes, cell cycle, etc. in oral cancer. In this review, we introduce the reports focused on the association of Fusobacterium species with cancer development and progression including oral, esophageal, and colon cancers.

  • Fusobacterium nucleatum
  • oral cancer
  • cancer development and progression

1. Introduction

Oral cancer, predominantly oral squamous cell carcinoma (OSCC), is a significant health problem and is regarded as the main cause of death from oral diseases in many countries. Traditional risk factors of oral cancer include alcohol abuse, tobacco and tobacco-derivate chewing, and oral virus infections. Other factors include infections, exposure to ionizing radiation, and environmental pollutants [1]. Thus, various causes of cancer are known to be closely involved in lifestyle choices, such as smoking, drinking, and diet.

Chronic inflammation caused by infections has been suggested to be one of the most important cause of cancers [2]. Indeed, infection of various viruses, bacteria, and parasites, such as Hepatitis B virus (HBV), Hepatitis B virus (HCV), Epstein–Barr virus (EBV), human papilloma virus (HPV), human herpes virus 8 (HHV8), human thymus-derived-cell leukemia/lymphoma virus-1 (HTLV-1), human immunodeficiency virus (HIV), Helicobacter pylori, Schistosomiasis, and liver flukes are well-known causes of cancer [2]. Recently, commensal bacteria are also involved in carcinogenesis. A huge number of different commensal bacteria naturally colonize in the human body in a relatively stable equilibrium. Microbial-immune network correlates gut bacteria with the whole-body health, and the failure of immune homeostasis manifests significant impact on various diseases, which might result in cancer [3–5][3][4][5]. Indeed, some commensal bacteria including Peptostreptococcus anaerobius [6], enterotoxigenic Bacteriodes fragiles [7], and Escherichia coli [8] are involved in carcinogenesis of colorectal cancer (CRC).

In the oral cavity, bacteria, fungi, viruses, and archaea naturally colonize in different habitats including the teeth, gingival sulcus, tongue, cheeks, hard and soft palates, and tonsils. The oral microbiota refers to a highly varied and complicated ecosystem of these organisms. Over 700 bacterial species are endemic to the oral cavity, and indigenous oral flora act to prevent the settlement of foreign bacteria. Some bacteria of the oral cavity are harmful and can cause serious disease, while many of the oral bacteria are in fact beneficial in preventing diseases. Thus, the oral cavity is inhabited by complex multispecies bacterial communities that usually exist in a balanced immunoinflammatory state with the host [9]. It is now established that many chronic inflammatory conditions are caused by an imbalance between host–microbiota interactions, resulting in a dysbiotic community, deregulated immune responses, and eventually disease outcomes [10]. Oral commensal bacteria play a critical role in the development of oral diseases, including periodontal disease and tooth loss, and maintenance of a normal oral physiological environment [11,12][11][12]. Moreover, oral commensal bacteria are known to be involved in the pathogenesis and development of systematic diseases, such as pneumonia, cardiovascular diseases, diabetes, dementia, etc. It has been of concern that oral commensal bacteria may be involved in the pathogenesis of OSCC [13,14][13][14]. However, it remains unclear the role of bacteria regarding carcinogenesis of OSCC, even though a lot of bacteria inhabit in the oral cavity. Interestingly, it recently has been shown that one of oral commensal bacteria, Fusobacterium species, especially, play a crucial role for the development of CRC [15–17][15][16][17]. As Fusobacterium species are commensal bacteria in the oral cavity, the cumulative evidences of Fusobacterium species in CRC make us hypothesize that Fusobacterium species may be involved in the pathogenesis and development of OSCC.

2. Fusobacterium Species and Oral Cancer

There are many reports showing that Fusobacterium were detected in OSCC tissues [50,51][18][19]. The ratio between aerobes and anaerobes within the biofilms on the surfaces of OSCC tissues was approximately 1:2, whereas that in the healthy control was 2:1, indicating that OSCC surfaces provide an important reservoir for anaerobic bacteria [52][20]. F. nucleatum subsp. polymorphum was the most significantly overrepresented species in OSCC compared to the control group with deep-epithelium swabs [53][21]. Perera et al. also reported that the Fusobacterium was enriched in OSCC biopsy compared to fibroepithelial polyp as a control [54][22]. Moreover, significantly greater bacterial diversity was observed in the swab of OSCC sites than that of normal sites [55][23]. Thus, distribution of bacteria including Fusobacterium in OSCC tissues may be distinct from that in healthy oral mucosal tissues. Yang et al. reported that F. periodonticum and several bacteria in oral rinse samples were associated with OSCC, and they progressively increased in abundance from stage I to stage IV [56][24].

It has been shown that there are specific associations among bacteria within dental plaque by cluster analysis using subgingival plaque samples [70,71][25][26]. As shown in Figure 1, various bacteria exist as shown in the pyramid. F. nucleatum is in the middle of pyramid. Among the species in the middle of pyramid, F. nucleatum is dominant in the dental biofilm at a later stage of plaque formation. As described above, Fusobacterium infection affects the tumorigenesis and development of OSCC through various responses (Figure 1). However, the target molecules of Fusobacterium are still unknown. Further studies will be required for clarifying the evidence of Fusobacterium involvement in tumorigenesis and development of OSCC.

Figure 1. Schematic model for the involvement of Fusobacterium species in oral carcinogenesis and cancer progression. In a dental plaque, various bacteria exist as shown in the pyramid. The base of the pyramid is comprised of species thought to colonize the tooth surface and proliferate at an early stage. Then, complex species in the middle of pyramid becomes numerically more dominant later and is thought to bridge the early colonizers. Finally, the complex species in the top of the pyramid numerically more dominant at late stages in plaque development. Among them, Fusobacterium species may adhere with oral keratinocyte or oral cancer cells via interaction between FadA/Fap2 and E-cadherin. This interaction may induce carcinogenesis and cancer progression.

3. Conclusion

F. nucleatum is well known oral commensal bacterium that forms typical dental plaque on human teeth is involved periodontal diseases. The involvement of F. nucleatum in carcinogenesis and the development of CRC has attracted attention in the field of CRC research. Importantly, the enrichment of F. nucleatum is frequently observed in OSCC tissues compared to healthy oral mucosal tissues. However, the roles of F. nucleatum in OSCC are still unclear. It is also necessary to investigate whether the mechanism of F. nucleatum in OSCC overlaps with that in CRC. We suggest that oral hygiene managements for reducing the amount of F. nucleatum may contribute to the prevention of OSCC and CRC. Moreover, various commensal bacteria exist in the oral cavity. Therefore, it is interesting to examine the relationship between F. nucleatum and other bacteria in the tumorigenesis and development of OSCC.

References

  1. Anand, P.; Kunnumakkara, A.B.; Sundaram, C.; Harikumar, K.B.; Tharakan, S.T.; Lai, O.S.; Sung, B.; Aggarwal, B.B. Cancer is a preventable disease that requires major lifestyle changes. Res. 2008, 25, 2097–2116.
  2. Kuper, H.; Adami, H.O.; Trichopoulos, D. Infections as a major preventable cause of human cancer. Intern Med. 2000, 248, 171–183.
  3. Blumberg, R.; Powrie, F. Microbiota, disease, and back to health: A metastable journey. Transl. Med. 2012, 4, rv7.
  4. Erdman, S.E.; Poutahidis, T. Gut bacteria and cancer. Biochim Biophys Acta (BBA)-Rev. Cancer 2015, 1856, 86–90.
  5. Erdman, S.E.; Rao, V.P.; Olipitz, W.; Taylor, C.L.; Jackson, E.A.; Levkovich, T.; Lee, C.W.; Horwitz, B.H.; Fox, J.G.; Ge, Z.; et al. Unifying roles for regulatory T cells and inflammation in cancer. J. Cancer 2010, 126, 1651–1665.
  6. Tsoi, H.; Chu, E.S.H.; Zhang, X.; Sheng, J.; Nakatsu, G.; Ng, S.C.; Chan, A.W.H.; Chan, F.K.L.; Sung, J.J.Y.; Yu, J. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology 2017, 152, 1419–1433.e5.
  7. Thiele Orberg, E.; Fan, H.; Tam, A. J.; Dejea, C.M.; Destefano Shields, C.E.; Wu, S.; Chung, L.; Finard, B.B.; Wu, X.; Fathi, P.; Ganguly, S.; et al. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol. 2017, 10, 421–433.
  8. Zhang, S.; Fu, J.; Dogan, B.; Scherl, E.J.; Simpson, K.W. 5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity. Antibiot. 2018, 71, 950–961.
  9. Hajishengallis, G.; Lamont, R.J. Beyond the red complex and into more complexity: The polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Oral Microbiol. 2012, 27, 409–419.
  10. Mohammed, H.; Varoni EM.; Cochis, A.; Cordaro, M.; Gallenzi, P.; Patini, R.; Staderini, E.; Lajolo, C.; Rimondini, L.; Rocchetti, V. Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature. Biomedicines 2018, 6, 115.
  11. Abiko, Y.; Sato, T.; Mayanagi, G.; Takahashi, N. Profiling of subgingival plaque biofilm microflora from periodontally healthy subjects and from subjects with periodontitis using quantitative real-time PCR. Periodontal Res. 2010, 45, 389–395.
  12. Preza, D.; Olsen, I.; Willumsen, T.; Boches, S.K.; Cotton, S.L.; Grinde, B.; Paster, B.J. Microarray analysis of the microflora of root caries in elderly. J. Clin. Microbiol. Infect Dis. 2009, 28, 509–517.
  13. Zhang, L.; Liu, Y.; Zheng, H.J.; Zhang, C.P. The Oral Microbiota May Have Influence on Oral Cancer. Front Cell Infect Microbiol. 2020, 9, 476.
  14. Kudo, Y.; Tada, H.; Fujiwara, N.; Tada, Y.; Tsunematsu, T.; Miyake, Y.; Ishimaru, N. Oral environment and cancer. Genes Environ. 2016, 38, 13.
  15. Rubinstein, M.R.; Wang, X.; Liu, W.; Hao, Y.; Cai, G.; Han, Y.W. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 2013, 14, 195–206.
  16. Gur, C.; Ibrahim, Y.; Isaacson, B.; Yamin, R.; Abed, J.; Gamliel, M.; Enk, J.; Bar-On, Y.; Stanietsky-Kaynan, N.; Coppenhagen-Glazer, S.; et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 2015, 42, 344–355.
  17. Abed, J.; Emgard, J.E.; Zamir, G.; Faroja, M.; Almogy, G.; Grenov, A.; Sol, A.; Naor, R.; Pikarsky, E.; Atlan, K.A.; et al. Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. Cell Host Microbe 2016, 20, 215–225.
  18. Long, S.; Prober, C.; Fischer, M. Principles and Practice of Pediatric Infectious Diseases, 5th ed.; Elsevier: Amsterdam, The Netherlands, 2017; pp. 1015–1017.
  19. Citron, D.M., Update on the taxonomy and clinical aspects of the genus fusobacterium. Infect Dis. 2002, 35 (Suppl 1), S22–S27.
  20. Patini, R.; Staderini, E.; Lajolo, C.; Lopetuso, L.; Mohammed, H.; Rimondini, L.; Rocchetti, V.; Franceschi, F.; Cordaro, M.; Gallenzi, P. Relationship between oral microbiota and periodontal disease: A systematic review. Rev. Med. Pharmacol. Sci. 2018, 22, 5775–5788.
  21. Kolenbrander, P.E.; Andersen, R.N.; Blehert, D.S.; Egland, P.G.; Foster, J.S.; Palmer, R.J., Jr. Communication among oral bacteria. Mol. Biol. Rev. 2002, 66, 486–505.
  22. Kolenbrander, P.E. Oral microbial communities: Biofilms, interactions, and genetic systems. Rev. Microbiol. 2000, 54, 413–437.
  23. Han, Y.W.; Ikegami, A.; Rajanna, C.; Kawsar, H.I.; Zhou, Y.; Li, M.; Sojar, H.T.; Genco, R.J.; Kuramitsu, H.K.; Deng, C.X. Identification and characterization of a novel adhesin unique to oral fusobacteria. Bacteriol. 2005, 187, 5330–5340.
  24. Xu, M.; Yamada, M.; Li, M.; Liu, H.; Chen, S.G.; Han, Y.W. FadA from Fusobacterium nucleatum utilizes both secreted and nonsecreted forms for functional oligomerization for attachment and invasion of host cells. Biol. Chem. 2007, 282, 25000–25009.
  25. Amano, A. Bacterial adhesins to host components in periodontitis. 2000 2010, 52, 12–37.
  26. Kaufman, J.; DiRienzo, J.M. Isolation of a corncob (coaggregation) receptor polypeptide from Fusobacterium nucleatum. Infect Immun. 1989, 57, 331–337.
  27. Kinder, S.A.; Holt, S.C. Localization of the Fusobacterium nucleatum T18 adhesin activity mediating coaggregation with Porphyromonas gingivalis T22. Bacteriol. 1993, 175, 840–850.
  28. Shaniztki, B.; Hurwitz, D.; Smorodinsky, N.; Ganeshkumar, N.; Weiss, E.I. Identification of a Fusobacterium nucleatum PK1594 galactose-binding adhesin which mediates coaggregation with periopathogenic bacteria and hemagglutination. Infect Immun. 1997, 65, 5231–5237.
  29. Castellarin, M.; Warren, R.L.; Freeman, J.D.; Dreolini, L.; Krzywinski, M.; Strauss, J.; Barnes, R.; Watson, P.; Allen-Vercoe, E.; Moore, R.A.; et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012, 22, 299–306.
  30. Kostic, A.D.; Gevers, D.; Pedamallu, C.S.; Michaud, M.; Duke, F.; Earl, A.M.; Ojesina, A.I.; Jung, J.; Bass, A.J.; Tabernero, J.; et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012, 22, 292–298.
  31. Bullman, S.; Pedamallu, C.S.; Sicinska, E.; Clancy, T.E.; Zhang, X.; Cai, D.; Neuberg, D.; Huang, K.; Guevara, F.; Nelson, T.; et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 2017, 358, 1443–1448.
  32. Komiya, Y.; Shimomura, Y.; Higurashi, T.; Sugi, Y.; Arimoto, J.; Umezawa, S.; Uchiyama, S.; Matsumoto, M.; Nakajima, A. Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity. Gut 2019, 68, 1335–1337.
  33. Yang, Y.; Weng, W.; Peng, J.; Hong, L.; Yang, L.; Toiyama, Y.; Gao, R.; Liu, M.; Yin, M.; Pan, C.; et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappab, and up-regulating expression of MicroRNA-21. Gastroenterology 2017, 152, 851–866e24.
  34. Li, YY.; Ge, QX.; Cao, J.; Zhou, Y.J.; Du, Y.L.; Shen, B.; Wan, Y.J.; Nie, Y.Q. Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J.J. Gastroenterol. 2016, 22, 3227–3233.
  35. Yan, X.; Liu, L.; Li, H.; Qin, H.; Sun, Z. Clinical significance of Fusobacterium nucleatum, epithelial-mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients. Onco Targets Ther. 2017, 10, 5031–5046.
  36. Yu, T.; Guo, F.; Yu, Y.; Sun, T.; Ma, D.; Han, J.; Qian, Y.; Kryczek, I.; Sun, D.; Nagarsheth, N.; et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017, 170, 548–563.e16.
  37. Kostic, A.D.; Chun, E.; Robertson, L.; Glickman, J.N.; Gallini, C.A.; Michaud, M.; Clancy, T.E.; Chung, D.C.; Lochhead, P.; Hold, G.L.; et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013, 14, 207–215.
  38. Chen, S.; Su, T.; Zhang, Y.; Lee, A.; He, J.; Ge, Q.; Wang, L.; Si, J.; Zhuo, W.; Wang, L. Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7. Gut Microbes 2020, 11, 511–525.
  39. Bryant, D.M.; Stow, J.L. The ins and outs of E-cadherin trafficking. Trends Cell Biol. 2004, 14, 427–434.
  40. Peifer, M.; Polakis, P. Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus. Science 2000, 287, 1606–1609.
  41. Dorudi, S.; Sheffield, J.P.; Poulsom, R.; Northover, J.M.; Hart, I.R. E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. J. Pathol. 1993, 142, 981–986.
  42. Coppenhagen-Glazer, S.; Sol, A.; Abed, J.; Naor, R.; Zhang, X.; Han, Y.W.; Bachrach, G. Fap2 of Fusobacterium nucleatum is a galactose-inhibitable adhesin involved in coaggregation, cell adhesion, and preterm birth. Immun. 2015, 83, 1104–1113.
  43. Yang, G.Y.; Shamsuddin, A.M. Gal-GalNAc: A biomarker of colon carcinogenesis. Histopathol. 1996, 11, 801–806.
  44. Abed, J.; Maalouf, N.; Parhi, L.; Chaushu, S.; Mandelboim, O.; Bachrach, G. Tumor Targeting by Fusobacterium nucleatum: A Pilot Study and Future Perspectives. Cell Infect. Microbiol. 2017, 7, 295.
  45. Harada, Y.; Izumi, H.; Noguchi, H.; Kuma, A.; Kawatsu, Y.; Kimura, T.; Kitada, S.; Uramoto, H.; Wang, K.Y.; Sasaguri, Y.; et al. Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma. Tumour Biol. 2016, 37, 1357–1368.
  46. Kaźmierczak-Siedlecka, K.; Daca, A.; Fic, M.; van de Wetering, T.; Folwarski, M.; MakarewiczW. Therapeutic methods of gut microbiota modification in colorectal cancer management—Fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. Gut Microbes 2020, 11, 1518–1530.
  47. Baba, H. Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis. Cancer Res. 2016, 22, 5574–5581.
  48. Shao, D.; Vogtmann, E.; Liu, A.; Qin, J.; Chen, W.; Abnet, C.C.; Wei, W. Microbial characterization of esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-risk region of China. Cancer 2019, 125, 3993–4002.
  49. Yamamura, K.; Baba, Y.; Nakagawa, S.; Mima, K.; Miyake, K.; Nakamura, K.; Sawayama, H.; Kinoshita, K.; Ishimoto, T.; Iwatsuki, M.; et al. Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma. Cancer Res. 2019, 25, 6170–6179.
  50. Nagy, K.N.; Sonkodi, I.; Szoke, I.; Nagy, E.; Newman, H.N. The microflora associated with human oral carcinomas. Oral Oncol. 1998, 34, 304–308.
  51. Schmidt, B.L.; Kuczynski, J.; Bhattacharya, A.; Huey, B.; Corby, P.M.; Queiroz, E.L.; Nightingale, K.; Kerr, A.R.; DeLacure, M.D.; Veeramachaneni, R.; et al. Changes in abundance of oral microbiota associated with oral cancer. PLoS ONE 2014, 9, e98741.
  52. Bolz, J.; Dosa, E.; Schubert, J.; Eckert, A.W. Bacterial colonization of microbial biofilms in oral squamous cell carcinoma. Oral Investig. 2014, 18, 409–414.
  53. Al-Hebshi, N.N.; Nasher, A.T.; Maryoud, M.Y.; Homeida, H.E.; Chen, T.; Idris, A.M.; Johnson, N.W. Inflammatory bacteriome featuring Fusobacterium nucleatum and Pseudomonas aeruginosa identified in association with oral squamous cell carcinoma. Rep. 2017, 7, 1834.
  54. Perera, M.; Al-Hebshi, N.N.; Perera, I.; Ipe, D.; Ulett, G.C.; Speicher, D.J.; Chen, T.; Johnson, N.W. Inflammatory Bacteriome and Oral Squamous Cell Carcinoma. Dent. Res. 2018, 97, 725–732.
  55. Zhao, H.; Chu, M.; Huang, Z.; Yang, X.; Ran, S.; Hu, B.; Zhang, C.; Liang, J. Variations in oral microbiota associated with oral cancer. Rep. 2017, 7, 11773.
  56. Yang, C.Y.; Yeh, Y.M.; Yu, H.Y.; Chin, C.Y.; Hsu, C.W.; Liu, H.; Huang, P.J.; Hu, S.N.; Liao, C.T.; Chang, K.P.; et al. Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging. Microbiol. 2018, 9, 862.
  57. Han, Y.W.; Shi, W.; Huang, G.T.; Kinder Haake, S.; Park, N.H.; Kuramitsu, H.; Genco, R.J. Interactions between periodontal bacteria and human oral epithelial cells: Fusobacterium nucleatum adheres to and invades epithelial cells. Immun. 2000, 68, 3140–3146.
  58. Uitto, V.J.; Baillie, D.; Wu, Q.; Gendron, R.; Grenier, D.; Putnins, E.E.; Kanervo, A.; Firth, J.D. Fusobacterium nucleatum increases collagenase 3 production and migration of epithelial cells. Immun. 2005, 73, 1171–1179.
  59. Binder Gallimidi, A.; Fischman, S.; Revach, B.; Bulvik, R.; Maliutina, A.; Rubinstein, A.M.; Nussbaum, G.; Elkin, M. Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model. Oncotarget 2015, 6, 22613–22623.
  60. Nieto, M.A.; Huang, R.Y.; Jackson, R.A.; Thiery, J.P. Emt: 2016. Cell 2016, 166, 21–45.
  61. Zhang, S.; Li, C.; Liu, J.; Geng, F.; Shi, X.; Li, Q.; Lu, Z.; Pan, Y. Fusobacterium nucleatum promotes epithelial-mesenchymal transiton through regulation of the lncRNA MIR4435-2HG/miR-296-5p/Akt2/SNAI1 signaling pathway. FEBS J. 2020, doi:1111/febs.15233.
  62. Bednarz-Knoll, N.; Alix-Panabieres, C.; Pantel, K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 2012, 31, 673–687.
  63. Saitoh, M. Involvement of partial EMT in cancer progression. Biochem. 2018, 164, 257–264.
  64. Kisoda, S.; Shao, W.; Fujiwara, N.; Mouri, Y.; Tsunematsu, T.; Jin, S.; Arakaki, R.; Ishimaru, N.; Kudo, Y. Prognostic value of partial EMT-related genes in head and neck squamous cell carcinoma by a bioinformatic analysis. Oral Dis. 2020, doi:10.1111/odi.13351.
  65. Fujiwara, N.; Shao, W.; Yoshida, K.; Arakaki, R.; Ozaki, K.; Ishimaru, N.; Kudo, Y. The effects of Fusobacterium nucleatum in oral cancer cells. In Proceedings of the 38th Japan Society for Molecular Pathology, Hyogo, Japan, 19th July 2019.
  66. Lee, C.H.; Chang, J.S.; Syu, S.H.; Wong, T.S.; Chan, J.Y.; Tang, Y.C.; Yang, Z.P.; Yang, W.C.; Chen, C.T.; Lu, S.C.; et al. IL-1beta promotes malignant transformation and tumor aggressiveness in oral cancer. Cell Physiol. 2015, 230, 875–884.
  67. Aral, K.; Milward, M.R.; Gupta, D.; Cooper, P.R. Effects of Porphyromonas gingivalis and Fusobacterium nucleatum on inflammasomes and their regulators in H400 cells. Oral Microbiol. 2020, 35, 158–167.
  68. Sasabe, E.; Tomomura, A.; Kitamura, N.; Yamamoto, T. Metal nanoparticles-induced activation of NLRP3 inflammasome in human oral keratinocytes is a possible mechanism of oral lichenoid lesions. Toxicol In Vitro 2020, 62, 104663.
  69. Geng, F.; Zhang, Y.; Lu, Z.; Zhang, S.; Pan, Y. Fusobacterium nucleatum Caused DNA Damage and Promoted Cell Proliferation by the Ku70/p53 Pathway in Oral Cancer Cells. DNA Cell Biol. 2020, 39, 144–151.
  70. Socransky, S.S.; Haffajee, A.D.; Cugini, M.A.; Smith, C.; Kent, R.L., Jr. Microbial complexes in subgingival plaque. J.J. Clin. Periodontol. 1998, 25, 134–144.
  71. Socransky, S.S.; Haffajee, A.D. Dental biofilms: Difficult therapeutic targets. 2000 2002, 28, 12–55.

References

  1. Anand, P.; Kunnumakkara, A.B.; Sundaram, C.; Harikumar, K.B.; Tharakan, S.T.; Lai, O.S.; Sung, B.; Aggarwal, B.B. Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res. 2008, 25, 2097–2116.
  2. Kuper, H.; Adami, H.O.; Trichopoulos, D. Infections as a major preventable cause of human cancer. J. Intern Med. 2000, 248, 171–183.
  3. Blumberg, R.; Powrie, F. Microbiota, disease, and back to health: A metastable journey. Sci. Transl. Med. 2012, 4, rv7.
  4. Erdman, S.E.; Poutahidis, T. Gut bacteria and cancer. Biochim Biophys Acta (BBA)-Rev. Cancer 2015, 1856, 86–90.
  5. Erdman, S.E.; Rao, V.P.; Olipitz, W.; Taylor, C.L.; Jackson, E.A.; Levkovich, T.; Lee, C.W.; Horwitz, B.H.; Fox, J.G.; Ge, Z.; et al. Unifying roles for regulatory T cells and inflammation in cancer. Int. J. Cancer 2010, 126, 1651–1665.
  6. Tsoi, H.; Chu, E.S.H.; Zhang, X.; Sheng, J.; Nakatsu, G.; Ng, S.C.; Chan, A.W.H.; Chan, F.K.L.; Sung, J.J.Y.; Yu, J. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology 2017, 152, 1419–1433.e5.
  7. Thiele Orberg, E.; Fan, H.; Tam, A. J.; Dejea, C.M.; Destefano Shields, C.E.; Wu, S.; Chung, L.; Finard, B.B.; Wu, X.; Fathi, P.; Ganguly, S.; et al. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol. 2017, 10, 421–433.
  8. Zhang, S.; Fu, J.; Dogan, B.; Scherl, E.J.; Simpson, K.W. 5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity. J. Antibiot. 2018, 71, 950–961.
  9. Hajishengallis, G.; Lamont, R.J. Beyond the red complex and into more complexity: The polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol. Oral Microbiol. 2012, 27, 409–419.
  10. Mohammed, H.; Varoni EM.; Cochis, A.; Cordaro, M.; Gallenzi, P.; Patini, R.; Staderini, E.; Lajolo, C.; Rimondini, L.; Rocchetti, V. Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature. Biomedicines 2018, 6, 115.
  11. Abiko, Y.; Sato, T.; Mayanagi, G.; Takahashi, N. Profiling of subgingival plaque biofilm microflora from periodontally healthy subjects and from subjects with periodontitis using quantitative real-time PCR. J. Periodontal Res. 2010, 45, 389–395.
  12. Preza, D.; Olsen, I.; Willumsen, T.; Boches, S.K.; Cotton, S.L.; Grinde, B.; Paster, B.J. Microarray analysis of the microflora of root caries in elderly. Eur. J. Clin. Microbiol. Infect Dis. 2009, 28, 509–517.
  13. Zhang, L.; Liu, Y.; Zheng, H.J.; Zhang, C.P. The Oral Microbiota May Have Influence on Oral Cancer. Front Cell Infect Microbiol. 2020, 9, 476.
  14. Kudo, Y.; Tada, H.; Fujiwara, N.; Tada, Y.; Tsunematsu, T.; Miyake, Y.; Ishimaru, N. Oral environment and cancer. Genes Environ. 2016, 38, 13.
  15. Rubinstein, M.R.; Wang, X.; Liu, W.; Hao, Y.; Cai, G.; Han, Y.W. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 2013, 14, 195–206.
  16. Gur, C.; Ibrahim, Y.; Isaacson, B.; Yamin, R.; Abed, J.; Gamliel, M.; Enk, J.; Bar-On, Y.; Stanietsky-Kaynan, N.; Coppenhagen-Glazer, S.; et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 2015, 42, 344–355.
  17. Abed, J.; Emgard, J.E.; Zamir, G.; Faroja, M.; Almogy, G.; Grenov, A.; Sol, A.; Naor, R.; Pikarsky, E.; Atlan, K.A.; et al. Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. Cell Host Microbe 2016, 20, 215–225.
  18. Nagy, K.N.; Sonkodi, I.; Szoke, I.; Nagy, E.; Newman, H.N. The microflora associated with human oral carcinomas. Oral Oncol. 1998, 34, 304–308.
  19. Schmidt, B.L.; Kuczynski, J.; Bhattacharya, A.; Huey, B.; Corby, P.M.; Queiroz, E.L.; Nightingale, K.; Kerr, A.R.; DeLacure, M.D.; Veeramachaneni, R.; et al. Changes in abundance of oral microbiota associated with oral cancer. PLoS ONE 2014, 9, e98741.
  20. Bolz, J.; Dosa, E.; Schubert, J.; Eckert, A.W. Bacterial colonization of microbial biofilms in oral squamous cell carcinoma. Clin. Oral Investig. 2014, 18, 409–414.
  21. Al-Hebshi, N.N.; Nasher, A.T.; Maryoud, M.Y.; Homeida, H.E.; Chen, T.; Idris, A.M.; Johnson, N.W. Inflammatory bacteriome featuring Fusobacterium nucleatum and Pseudomonas aeruginosa identified in association with oral squamous cell carcinoma. Sci. Rep. 2017, 7, 1834.
  22. Perera, M.; Al-Hebshi, N.N.; Perera, I.; Ipe, D.; Ulett, G.C.; Speicher, D.J.; Chen, T.; Johnson, N.W. Inflammatory Bacteriome and Oral Squamous Cell Carcinoma. J. Dent. Res. 2018, 97, 725–732.
  23. Zhao, H.; Chu, M.; Huang, Z.; Yang, X.; Ran, S.; Hu, B.; Zhang, C.; Liang, J. Variations in oral microbiota associated with oral cancer. Sci. Rep. 2017, 7, 11773.
  24. Yang, C.Y.; Yeh, Y.M.; Yu, H.Y.; Chin, C.Y.; Hsu, C.W.; Liu, H.; Huang, P.J.; Hu, S.N.; Liao, C.T.; Chang, K.P.; et al. Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging. Front. Microbiol. 2018, 9, 862.
  25. Socransky, S.S.; Haffajee, A.D.; Cugini, M.A.; Smith, C.; Kent, R.L., Jr. Microbial complexes in subgingival plaque. J.J. Clin. Periodontol. 1998, 25, 134–144.
  26. Socransky, S.S.; Haffajee, A.D. Dental biofilms: Difficult therapeutic targets. Periodontol. 2000 2002, 28, 12–55.
More